Axoltis Revenue and Competitors
Estimated Revenue & Valuation
- Axoltis's estimated annual revenue is currently $2.8M per year.
- Axoltis's estimated revenue per employee is $155,000
Employee Data
- Axoltis has 18 Employees.
- Axoltis grew their employee count by 13% last year.
Axoltis's People
| Name | Title | Email/Phone |
|---|
Axoltis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is Axoltis?
Axoltis pharma is a biopharmaceutical company dedicated to develop first-in-class disease-modifying drugs to treat patients with neurodegenerative or traumatic neurological disorders with high unmet medical needs. Our innovative approach: combining Preventative, Neuroprotective, Regenerative & Remodeling properties in a single drug, as the key to cure complex neurological disorders. Our products are first-in-class multifunctional peptides with high potential in many CNS disorders.
keywords:N/A
N/A
Total Funding
18
Number of Employees
$2.8M
Revenue (est)
13%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Axoltis News
2022-03-22 - Croissance de Marché mondial des lésions aiguës de la ...
Ltd., Vertex Pharmaceuticals Inc., Axoltis, K-STEMCELL Co., Ltd., and WAKAYAMA MEDICAL UNIVERSITY, among other domestic and global players.
Other Companies in Lyon
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.8M | 18 | -14% | N/A |
#2 | $1.6M | 18 | -44% | N/A |
#3 | $2.8M | 18 | -25% | N/A |
#4 | $2M | 20 | -13% | N/A |
#5 | $2.1M | 21 | N/A | N/A |